Global Point Of Care

Pediatric Cholesterol Screening

Unlock the potential in pediatric testing by screening to the NIH guidelines and reducing the risk associated with early CVD. Screen early for detection of familial hypercholestrolemia (FH) with the Cholestech LDXTM System. Contact us today to start pediatric lipid testing.

LPHeroPediatricUSCholestech
LPHeroPediatricUSCholestech
LPHeroPediatricUSCholestech
Understand your A1c Understand your A1c

PEDIATRIC CHOLESTEROL SCREENING

Unlock the potential in pediatric testing by screening to the NIH guidelines and reducing the risk associated with early CVD. Screen early for detection of familial hypercholestrolemia (FH) with the Cholestech LDXTM System. Contact us today to start pediatric lipid testing.

Identify CVD Risk in Minutes. Screen Now.

Reducing lifetime risk for cardiovascular disease (CVD) is the principle that underlies CVD prevention strategies, including those that begin in childhood.1 The big five heart disease and stroke factors (high blood pressure, high cholesterol, smoking or secondhand smoke, an unhealthy diet and physical inactivity) are rooted in childhood.2

Universal cholesterol screenings of children from ages 9-11, not only enables physicians to work with their patients and the child's caregiver to address any modifiable risk factors, but it also screens for the presence of familial hypercholesterolemia. Only 4-5% of children between 9-11 years of age are being screened.3

NIH Guidlines for Pediatric Lipid Testing

The NIH guidelines offer the most comprehensive and up-to-date approach to pediatric lipid screening, helping clinicians improve outcomes

Cholestech ldx

Benefits of screening with Cholestech LDX

The Cholestech LDX system uses a small, fingerstick sample, testing for lipids and glucose right at the point of care. This enables pediatricians and parents to have face-to-face conversations about modifiable or genetic risk factors.

Reliable and fast, the Cholestech LDX system has been the #1 choice for fingerstick lipid testing by healthcare professionals for over 25 years.

icon

Small 40 μL fingerstick sample

icon

Convenient for kids, parents and HCPs

icon

Accurate, reliable results in 5 minutes

lp poc vs central lab infographic 1457
lp poc vs central lab infographic 1457

Benefits of screening with Cholestech LDX

The Cholestech LDX system uses a small, fingerstick sample, testing for lipids and glucose right at the point of care. This enables pediatricians and parents to have face-to-face conversations about modifiable or genetic risk factors.

Reliable and fast, the Cholestech LDX system has been the #1 choice for fingerstick lipid testing by healthcare professionals for over 25 years.

icon

Small 40 μL fingerstick sample

icon

Convenient for kids, parents and HCPs

icon

Accurate, reliable results in 5 minutes

Cholestech ldx
lp poc vs central lab infographic 1457
lp poc vs central lab infographic 1457

Test for Familial Hypercholesterolemia

Familial hypercholesterolemia (FH) is a common genetic disorder leading to elevated low density lipoprotein cholesterol (LDL-C) from birth.4 Globally 1 out of 220 children, approximately one child has FH, and therefore an increased risk to suffer from early cardiovascular disease, or even early death.5

girl and mother with doctor

Cholestech LDX is not for use in children under the age of 2 years or patients with hyperbilirubinemia (elevated bilirubin levels).

References

  1. National Heart, Lung, and Blood Institute NIH Publication No. 12-7486 October 2012. http://www.ncsl.org/research/health/heart-disease-and-stroke-an-overview.aspx
  2. Journal of Clinical Lipidology (2020) doi: https://doi.org/10.1016/j.jacl.2020.01.013
  3. The FH Foundation. (2021, March 24). What is familial hypercholesterolemia. https://thefhfoundation.org/familial-hypercholesterolemia/what-is-familial-hypercholesterolemia
  4. McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. J Am Heart Assoc 2019;8:e013225.
  5. McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. J Am Heart Assoc 2019;8:e013225.